Impact of Pseudomonas aeruginosa Infection on Patients with Chronic Inflammatory Airway Diseases.

Autores de IIS La Fe

• 

  Miguel Ángel Martínez García

  Autor

Participantes ajenos a IIS La Fe

• Garcia-Clemente M
• de la Rosa D
• Máiz L
• Girón R
• Blanco M
• Olveira C
• Canton R

Grupos

• Neumología

  

  Leader

  Miguel Ángel Martínez García

Abstract

Pseudomonas aeruginosa ( P. aeruginosa ) is a ubiquitous and opportunistic microorganism and is considered one of the most significant pathogens that produce chronic colonization and infection of the lower respiratory tract, especially in people with chronic inflammatory airway diseases such as asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and bronchiectasis. From a microbiological viewpoint, the presence and persistence of P. aeruginosa over time are characterized by adaptation within the host that precludes any rapid, devastating injury to the host. Moreover, this microorganism usually develops antibiotic resistance, which is accelerated in chronic infections especially in those situations where the frequent use of antimicrobials facilitates the selection of "hypermutator P. aeruginosa strain". This phenomenon has been observed in people with bronchiectasis, CF, and the "exacerbator" COPD phenotype. From a clinical point of view, a chronic bronchial infection of P. aeruginosa has been related to more severity and poor prognosis in people with CF, bronchiectasis, and probably in COPD, but little is known on the effect of this microorganism infection in people with asthma. The relationship between the impact and treatment of P. aeruginosa infection in people with airway diseases emerges as an important future challenge and it is the most important objective of this review.

Keywords

• COPD, Pseudomonas aeruginosa, asthma, bronchiectasis, chronic bronchial infection, cystic fibrosis